Innate Pharma to Participate in Upcoming Investor Conference

Rhea-AI Summary

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) announced its participation in the Van Lanschot Kempen Life Sciences Conference 2023 on April 25-26 in Amsterdam. The company specializes in developing immunotherapies for cancer, leveraging its proprietary ANKET® platform. Key programs include lacutamab, targeting cutaneous and peripheral T cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca to enhance innovation. Headquartered in Marseille, France, Innate Pharma is committed to advancing cancer treatment through its clinical-stage biotechnology.

MARSEILLE, France--(BUSINESS WIRE)-- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the following upcoming investor conference:

• Van Lanschot Kempen Life Sciences Conference 2023
  Event Date: April 25-26, Amsterdam

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET^® multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn.

Information about Innate Pharma shares

ISIN code Ticker code LEI

FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005521/en/

Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Source: Innate Pharma SA

FAQ

What is the date of the Van Lanschot Kempen Life Sciences Conference 2023 for Innate Pharma?

The conference will take place on April 25-26, 2023.

Where is the Van Lanschot Kempen Life Sciences Conference 2023 being held?

The conference is being held in Amsterdam.

What is Innate Pharma's main focus in biotechnology?

Innate Pharma focuses on developing immunotherapies for cancer patients.

What are the proprietary programs of Innate Pharma?

Innate Pharma's lead programs include lacutamab and monalizumab.

Which companies collaborate with Innate Pharma?

Innate Pharma collaborates with Sanofi and AstraZeneca.